This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2014 Nov 27;371(22):2141-2.

doi: 10.1056/NEJMc1411800. Epub 2014 Nov 5.

Use of PER977 to reverse the anticoagulant effect of edoxaban

Jack E Ansell¹, Sasha H Bakhru, Bryan E Laulicht, Solomon S Steiner, Michael Grosso, Karen Brown, Victor Dishy, Robert J Noveck, James C Costin

Affiliations

PMID: 25371966
DOI: 10.1056/NEJMc1411800

Use of PER977 to reverse the anticoagulant effect of edoxaban

Jack E Ansell et al. N Engl J Med. 2014.

. 2014 Nov 27;371(22):2141-2.

doi: 10.1056/NEJMc1411800. Epub 2014 Nov 5.

Authors

Jack E Ansell¹, Sasha H Bakhru, Bryan E Laulicht, Solomon S Steiner, Michael Grosso, Karen Brown, Victor Dishy, Robert J Noveck, James C Costin

Affiliation

¹ Hofstra North Shore-LIJ School of Medicine, Hempstead, NY ansellje@gmail.com.

PMID: 25371966
DOI: 10.1056/NEJMc1411800

No abstract available

PubMed Disclaimer

Similar articles

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.
Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, Dishy V, Lanz HJ, Mercuri MF, Noveck RJ, Costin JC. Ansell JE, et al. Thromb Haemost. 2017 Jan 26;117(2):238-245. doi: 10.1160/TH16-03-0224. Epub 2016 Nov 17. Thromb Haemost. 2017. PMID: 27853809 Free PMC article. Clinical Trial.
Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
Kalathottukaren MT, Creagh AL, Abbina S, Lu G, Karbarz MJ, Pandey A, Conley PB, Kizhakkedathu JN, Haynes C. Kalathottukaren MT, et al. Blood Adv. 2018 Aug 28;2(16):2104-2114. doi: 10.1182/bloodadvances.2016003616. Blood Adv. 2018. PMID: 30135185 Free PMC article.
Clinical implications of reversal agents for direct oral anticoagulants.
Monagle S, Eikelboom JW, Ng KH, Bhagirath VC. Monagle S, et al. Future Cardiol. 2017 Mar;13(2):153-159. doi: 10.2217/fca-2016-0070. Epub 2017 Feb 13. Future Cardiol. 2017. PMID: 28198201 Review.
Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A, Strandberg K, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Lindahl TL. Hillarp A, et al. Scand J Clin Lab Invest. 2018 Nov-Dec;78(7-8):575-583. doi: 10.1080/00365513.2018.1522664. Epub 2018 Oct 2. Scand J Clin Lab Invest. 2018. PMID: 30278787
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Ruff CT, Giugliano RP, Antman EM. Ruff CT, et al. Circulation. 2016 Jul 19;134(3):248-61. doi: 10.1161/CIRCULATIONAHA.116.021831. Circulation. 2016. PMID: 27436881 Review.

See all similar articles

Cited by

ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events.
De Luca L, Pugliese FR, Susi B, Navazio A, Corda M, Fabbri A, Scicchitano P, Voza A, Vanni S, Bilato C, Geraci G, Gabrielli D, Grimaldi M, Colivicchi F, De Iaco F, Oliva F. De Luca L, et al. Eur Heart J Suppl. 2024 May 16;26(Suppl 2):ii211-ii220. doi: 10.1093/eurheartjsupp/suae033. eCollection 2024 Apr. Eur Heart J Suppl. 2024. PMID: 38784674 Free PMC article.
The Use of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Pharmacist's Perspective.
Stacy ZA, Richter SK. Stacy ZA, et al. Hosp Pharm. 2016 Jan;51(1):26-34. doi: 10.1310/hpj5101-26. Epub 2016 Jan 1. Hosp Pharm. 2016. PMID: 38745713 Free PMC article.
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
Cross B, Turner RM, Zhang JE, Pirmohamed M. Cross B, et al. Pharmacogenomics J. 2024 Mar 5;24(2):7. doi: 10.1038/s41397-024-00329-y. Pharmacogenomics J. 2024. PMID: 38443337 Free PMC article. Review.
Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?
Poenou G, Heestermans M, Lafaie L, Accassat S, Moulin N, Rodière A, Petit B, Duvillard C, Mismetti P, Bertoletti L. Poenou G, et al. Int J Mol Sci. 2023 Sep 22;24(19):14433. doi: 10.3390/ijms241914433. Int J Mol Sci. 2023. PMID: 37833881 Free PMC article. Review.
New High-Affinity Thrombin Aptamers for Advancing Coagulation Therapy: Balancing Thrombin Inhibition for Clot Prevention and Effective Bleeding Management with Antidote.
Ayass MA, Griko N, Pashkov V, Tripathi T, Zhang J, Ramankutty Nair R, Okyay T, Zhu K, Abi-Mosleh L. Ayass MA, et al. Cells. 2023 Sep 7;12(18):2230. doi: 10.3390/cells12182230. Cells. 2023. PMID: 37759453 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations